The patients who underwent Phbol-seq-based PGT-M had autosomal dominant genetic disease, namely, cardio-facio-cutaneous syndrome 3 involving the MAP2K1 gene; autosomal recessive genetic disease, namely, very-long chain acyl-CoA dehydrogenase deficiency (VLCAD) involving the ACADVL gene; or autosomal recessive genetic disease, namely, b-thalassemia involving the HBB gene. This evidence concerns the gene MAP2K1 and very long chain acyl-CoA dehydrogenase deficiency.